1. Scrip
  2. >>R&D

Parexel Execs On Obesity Drug Hurdles, Parexel GPT, India RWD Opportunity

 
• By Vibha Ravi

Parexel’s chief strategy officer Kushal Gohil, Clinical EVP Stephen Pyke and India head Sanjay Vyas share thoughts on possible hurdles to, and the cascading impact of obesity treatments, GenAI progress and the opportunities and challenges of real-world data in India, in the second of this two-part interview with Scrip.

Parexel's Kushal Gohil, Stephen Pyke, Sanjay Vyas
L to R - Parexel’s Kushal Gohil (chief strategy officer), Sanjay Vyas (EVP and MD for India) and Stephen Pyke (EVP, Clinical Data and Digital Services) • Source: Citeline/Scrip

Eli Lilly and Company and Novo Nordisk A/S have been expanding the indications for their drugs first approved to treat obesity to add to the already huge income such products have generated.

Meanwhile, it’s not just major firms like Roche Holding AG and Pfizer Inc. playing catch up, but biotechs like Zealand Pharma A/S and Structure Therapeutics, Inc. are also developing contenders for the top prize in obesity treatment

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: AstraZeneca CEO cautions Europe; Pfizer CEO optimistic on US tariffs, pricing; Merck & Co reassures on pipeline; Merck KGaA buys SpringWorks; and Akeso explains ivonescimab overall survival data.